Pharsight

Noxafil patents expiration

NOXAFIL's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5703079 MERCK SHARP DOHME Tetrahydrofuran antifungals
Aug, 2014

(9 years ago)

US5661151 MERCK SHARP DOHME Tetrahydrofuran antifungals
Jul, 2019

(4 years ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9750822 MERCK SHARP DOHME Sulfoalkyl ether cyclodextrin compositions
Mar, 2029

(4 years from now)

US10117951 MERCK SHARP DOHME Sulfoalkyl ether cyclodextrin compositions
Mar, 2029

(4 years from now)

US8410077 MERCK SHARP DOHME Sulfoalkyl ether cyclodextrin compositions
Mar, 2029

(4 years from now)

US9358297 MERCK SHARP DOHME Posaconazole intravenous solution formulations stabilized by substituted β-cyclodextrin
Jun, 2031

(7 years from now)

US9023790 MERCK SHARP DOHME Posaconazole intravenous solution formulations stabilized by substituted β-cyclodextrin
Jul, 2031

(7 years from now)

US9493582 MERCK SHARP DOHME Alkylated cyclodextrin compositions and processes for preparing and using the same
Feb, 2033

(8 years from now)

Noxafil is owned by Merck Sharp Dohme.

Noxafil contains Posaconazole.

Noxafil has a total of 8 drug patents out of which 2 drug patents have expired.

Expired drug patents of Noxafil are:

  • US5703079
  • US5661151

Noxafil was authorised for market use on 13 March, 2014.

Noxafil is available in solution;intravenous, tablet, delayed release;oral dosage forms.

Noxafil can be used as prophylaxis of invasive aspergillus and candida infections in adults and pediatric patients 2 years of age and older who are severely immunocompromised, prophylaxis of invasive aspergillus and candida infections.

The generics of Noxafil are possible to be released after 27 February, 2033.

Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) May 31, 2024
Orphan Drug Exclusivity(ODE-355) Jun 17, 2028
New Indication(I-881) Jun 17, 2024

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using POSACONAZOLE ingredient

Market Authorisation Date: 13 March, 2014

Treatment: Prophylaxis of invasive aspergillus and candida infections in adults and pediatric patients 2 years of age and older who are severely immunocompromised; Prophylaxis of invasive aspergillus and candida...

Dosage: SOLUTION;INTRAVENOUS; TABLET, DELAYED RELEASE;ORAL

How can I launch a generic of NOXAFIL before it's drug patent expiration?
More Information on Dosage

NOXAFIL family patents

Family Patents
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5703079 SCHERING Tetrahydrofuran antifungals
Aug, 2014

(9 years ago)

US6958337 SCHERING Crystalline antifungal polymorph
Oct, 2018

(5 years ago)

US5661151 SCHERING Tetrahydrofuran antifungals
Jul, 2019

(4 years ago)

US8263600 SCHERING Antifungal composition with enhanced bioavailability
Apr, 2022

(2 years ago)

Noxafil is owned by Schering.

Noxafil contains Posaconazole.

Noxafil has a total of 4 drug patents out of which 4 drug patents have expired.

Expired drug patents of Noxafil are:

  • US5703079
  • US6958337
  • US5661151
  • US8263600

Noxafil was authorised for market use on 15 September, 2006.

Noxafil is available in suspension;oral dosage forms.

Noxafil can be used as prophylaxis of invasive aspergillus and candida infections and treatment of oropharyngeal candidiasis.

Drug patent challenges can be filed against Noxafil from 15 September, 2010.

The generics of Noxafil are possible to be released after 01 April, 2022.

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Sep 15, 2011

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using POSACONAZOLE ingredient

NCE-1 date: 15 September, 2010

Market Authorisation Date: 15 September, 2006

Treatment: Prophylaxis of invasive aspergillus and candida infections and treatment of oropharyngeal candidiasis

Dosage: SUSPENSION;ORAL

How can I launch a generic of NOXAFIL before it's drug patent expiration?
More Information on Dosage

NOXAFIL family patents

Family Patents